- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Advances in Alzheimer’s Disease Drug Development ; volume:13 ; number:1 ; day:25 ; month:3 ; year:2015 ; pages:1-7 ; date:12.2015
BMC medicine ; 13, Heft 1 (25.3.2015), 1-7, 12.2015
- Urheber
-
Rafii, Michael S.
- Beteiligte Personen und Organisationen
-
Aisen, Paul S.
SpringerLink (Online service)
- DOI
-
10.1186/s12916-015-0297-4
- URN
-
urn:nbn:de:1111-201611047092
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rafii, Michael S.
- Aisen, Paul S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Advances in Drug Therapy for Alzheimer’s Disease
Alzheimer’s Disease Drug Development Pipeline 2020
The Alzheimer’s disease drug development landscape
Geroscience and Alzheimer’s Disease Drug Development
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Advances in Drug Therapy for Alzheimer’s Disease
Alzheimer’s Disease Drug Development Pipeline 2020
The Alzheimer’s disease drug development landscape
Geroscience and Alzheimer’s Disease Drug Development
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Advances in Drug Therapy for Alzheimer’s Disease
Alzheimer’s Disease Drug Development Pipeline 2020
The Alzheimer’s disease drug development landscape
Geroscience and Alzheimer’s Disease Drug Development
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies
Advances in the development of new biomarkers for Alzheimer’s disease
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Repurposed agents in the Alzheimer’s disease drug development pipeline
The “rights” of precision drug development for Alzheimer’s disease
Drug development in Alzheimer’s disease: the path to 2025
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline